Junlan Yang

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Randomized Trial of Lapatinib Versus Placebo Added to Paclitaxel in the Treatment of Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancer

Zhongzhen Guan, Binghe Xu, Michelle DeSilvio et al. · Journal of Clinical Oncology · 2013 · 139 citations

Medicine, Oncology, Pharmacology +17

Modelling of marine traffic flow complexity

Yuanqiao Wen, Yamin Huang, Chunhui Zhou et al. · Ocean Engineering · 2015 · 118 citations

Engineering, Marine Engineering, Ocean Engineering +12

Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial

Zefei Jiang, Quchang Ouyang, Tao Sun et al. · Nature Medicine · 2024 · 112 citations

Medicine, Oncology, Pharmacology +14

Cytotoxic T lymphocyte antigen 4 expression in human breast cancer: implications for prognosis

Haiming Yu, Junlan Yang, Shunchang Jiao et al. · Cancer Immunology Immunotherapy · 2015 · 106 citations · Full text

Life Sciences, Oncology, Pathology +16